Silexion Therapeutics Urges Shareholders to Vote Ahead of March 16 Extraordinary General Meeting

Rhea-AI Summary

Silexion Therapeutics (NASDAQ:SLXN) reminds shareholders of an Extraordinary General Meeting on March 16, 2026 to vote on two capital actions: increasing authorized share capital from US$121,500 (9,000,000 shares) to US$796,500 (59,000,000 shares), and amending its 2024 Equity Incentive Plan evergreen to yield a 10% fully diluted reserve. The Board unanimously recommends voting FOR all proposals to support clinical development of SIL-204, potential Nasdaq compliance measures, and employee incentive capacity. Shareholders are urged to vote promptly; proxy assistance is available via Laurel Hill Advisory Group.

Positive

• Authorized shares increased to 59,000,000 provides flexibility
• Evergreen amendment targets a 10% fully diluted equity pool
• Board unanimously recommends voting FOR all proposals

Negative

• Potential dilution from adding 50,000,000 ordinary shares
• Evergreen increase to 10% may expand share issuance pressure
• Proposals linked to Nasdaq compliance actions imply listing risk

News Market Reaction – SLXN

-1.79%

1 alert

-1.79% News Effect

On the day this news was published, SLXN declined 1.79%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Authorized capital (current): US$121,500 Authorized shares (current): 9,000,000 ordinary shares Authorized capital (proposed): US$796,500 +5 more

8 metrics

Authorized capital (current) US$121,500 Existing authorized share capital before proposed increase

Authorized shares (current) 9,000,000 ordinary shares Existing authorized ordinary shares

Authorized capital (proposed) US$796,500 Proposed authorized share capital after EGM approval

Authorized shares (proposed) 59,000,000 ordinary shares Proposed authorized ordinary shares after EGM

Share increase 50,000,000 ordinary shares Incremental authorized shares requested at EGM

Par value US$0.0135 per share Par value of each ordinary share

Evergreen (current) 5% of issued and outstanding shares Current annual equity incentive plan increase

Evergreen (proposed) 10% on fully diluted basis Proposed aggregate equity pool across all plans

Market Reality Check

Price: $1.65 Vol: Volume 18,801 is below th...

normal vol

$1.65 Last Close

Volume Volume 18,801 is below the 20-day average of 26,314, suggesting limited pre-EGM positioning. normal

Technical Shares at $1.68 are trading below the 200-day MA of $6.04 and 93.71% below the 52-week high of $26.70.

Peers on Argus

SLXN was up 1.06% while several biotech peers showed stronger mixed moves (e.g.,...

SLXN was up 1.06% while several biotech peers showed stronger mixed moves (e.g., GLTO +6.46%, QLGN +7.72%, ENTO -5.68%). With peer momentum flags empty and no same-day peer headlines, the reaction appears driven more by SLXN-specific governance and capital-structure developments than a broad sector rotation.

Historical Context

5 past events · Latest: Jan 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 21	Conference participation	Positive	-5.8%	Management attendance at RNAi summit and investor meetings on SIL204 program.
Jan 06	Corporate update	Positive	-4.1%	CEO letter highlighting 2025 achievements and 2026 SIL204 milestones.
Dec 16	Clinical filing	Positive	+1.2%	Phase 2/3 trial application for SIL204 in Israel targeting Q2 2026 start.
Dec 02	Regulatory feedback	Positive	-7.6%	Positive Scientific Advice from German authority on Phase 2/3 trial design.
Nov 26	Conference presentation	Positive	+20.4%	Presentation at Noble Capital Markets emerging growth conference.

Pattern Detected

Recent SLXN news has often seen mixed or contrarian reactions, with several positive clinical and corporate updates followed by negative price moves.

Recent Company History

Over the past six months, SLXN has focused on advancing SIL204 toward a Phase 2/3 pancreatic cancer trial while maintaining its Nasdaq listing and investor visibility. Positive regulatory interactions with BfArM, a Phase 2/3 application in Israel, and conference participation on Nov 26 and Jan 27–29 have produced both gains (e.g., +20.42% on Nov 26, 2025) and declines (e.g., -7.61% on Dec 2, 2025). Today’s EGM-focused communication fits this pattern of capital-markets and development milestones occurring in close succession.

Regulatory & Risk Context

Active S-3 Shelf · $4.9 million

Shelf Active

Active S-3 Shelf Registration 2025-10-31

$4.9 million registered capacity

An effective resale S-3 filed on Oct 31, 2025 covers up to 1,292,348 ordinary shares and 372 warrants. SLXN would receive up to $4.9 million only if 344,063 registered warrants are exercised for cash. The current EGM proposals to expand authorized share capital and increase the equity incentive pool sit alongside this existing resale capacity.

Market Pulse Summary

This announcement centers on an EGM to expand authorized share capital by 50,000,000 shares and to d...

Analysis

This announcement centers on an EGM to expand authorized share capital by 50,000,000 shares and to double the evergreen equity pool to 10% on a fully diluted basis. It connects directly to funding needs for the SIL204 program and Nasdaq compliance, following prior financings and an existing resale S-3. Investors may track the March 16 vote outcome, subsequent capital-raising activity, and progress toward the planned Phase 2/3 trial.

Key Terms

authorized share capital, equity incentive plan, evergreen provision, Nasdaq listing requirements, +3 more

7 terms

authorized share capital financial

"Authorized Share Capital Increase Proposal: An increase to the authorized share capital of the Company"

The maximum number of shares a company is legally allowed to issue according to its governing documents. Think of it as the size of the blank checkbook a company keeps for selling ownership stakes: it sets an upper limit but does not mean all shares are in circulation. Investors care because a larger authorized amount makes it easier for the company to raise money or grant stock-based pay, which can dilute existing holdings and affect control and value per share.

equity incentive plan financial

"amendment to the Silexion Therapeutics Corp 2024 Equity Incentive Plan (the “2024 Plan”)"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

evergreen provision financial

"added annually on January 1st under the “evergreen” provision of Section 5(b)(i) of the 2024 Plan"

An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.

Nasdaq listing requirements regulatory

"take actions (if necessary) to maintain compliance with Nasdaq listing requirements"

NASDAQ listing requirements are the financial, governance and disclosure rules a company must meet to have its shares traded on the NASDAQ stock exchange. Think of them as the standards a business must pass to join an exclusive marketplace — they affect whether a stock can be bought easily, how much public information the company must provide, and how investors judge its credibility and risk. Meeting these rules can boost liquidity and investor confidence.

proxy solicitor regulatory

"please contact Laurel Hill Advisory Group, the Company’s proxy solicitor, toll-free at"

A proxy solicitor is a professional firm or individual hired by a company or a shareholder to contact other shareholders and gather their votes or signed proxy cards for an upcoming shareholder meeting. Think of them as paid canvassers who explain proposals and collect votes; their work can determine outcomes like board elections, mergers, or policy changes and signals how contested or important a vote is to investors.

proxy card regulatory

"If you lost your proxy card, have any questions or require assistance voting your shares"

A proxy card is a document that allows shareholders to give someone else the authority to vote on their behalf at a company’s meeting. Think of it as a permission slip that ensures a shareholder’s interests are represented even if they cannot attend in person. For investors, proxy cards are important because they influence company decisions and governance, giving them a way to participate indirectly.

beneficial owner regulatory

"If you are a beneficial owner and hold your shares through a broker, please follow"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

AI-generated analysis. Not financial advice.

Grand Cayman, Cayman Island, March 05, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, reminds its shareholders of the upcoming Extraordinary General Meeting of Shareholders (the "EGM"), scheduled to be held on March 16, 2026.

At the EGM, shareholders will be asked to vote on proposals relating to:

•  Authorized Share Capital Increase Proposal: An increase to the authorized share capital of the Company by 50,000,000 ordinary shares, from US$121,500 divided into 9,000,000 ordinary shares of a par value of US$0.0135 each (which is our current authorized share capital), to US$796,500 divided into 59,000,000 ordinary shares of a par value of US$0.0135 each.
  
  
• Equity Incentive Plan Evergreen Increase Proposal: An amendment to the Silexion Therapeutics Corp 2024 Equity Incentive Plan (the “2024 Plan”), effective as of January 1, 2026, to increase the number of ordinary shares added annually on January 1st under the “evergreen” provision of Section 5(b)(i) of the 2024 Plan from (i) 5% of the Company’s issued and outstanding ordinary shares, to (ii) such number of ordinary shares as yields a pool of ordinary shares reserved under all equity incentive plans of the Company that constitutes, in the aggregate, 10% of the issued and outstanding ordinary shares on a fully diluted basis..

Your Vote Is Important

By voting FOR all proposals, shareholders will enable the Company to advance its clinical development of SIL-204, advance its long-term strategic vision, including potential strategic initiatives, take actions (if necessary) to maintain compliance with Nasdaq listing requirements, and support the Company’s ability to attract, retain, and incentivize employees, officers, and directors. These proposals, taken together, position the Company to continue executing on its clinical development of SIL-204 strategy while giving the Board the tools necessary to pursue emerging opportunities that may drive future growth and shareholder value.

Every shareholder vote is important, regardless of the number of shares held. The presence of a quorum is required in order for the EGM to proceed, and timely voting by shareholders is essential.  

After careful consideration, the Board of Directors has determined that the proposals to be presented at the EGM are in the best interests of the Company and its shareholders and therefore unanimously recommends that shareholders vote FOR all proposed resolutions.

Voting Instructions

Shareholders are strongly encouraged to vote as soon as possible to ensures your shares are represented at the EGM.

• If you lost your proxy card, have any questions or require assistance voting your shares, please contact Laurel Hill Advisory Group, the Company’s proxy solicitor, toll-free at (888) 742‑1305 (from the United States and Canada) or at (516) 933‑3100 (from other locations).
• Shareholders of record (Registered Shareholder) may vote by returning their proxy card or voting online at www.cstproxyvote.com using the control number provided in their proxy materials.

• If you are a beneficial owner and hold your shares through a broker, please follow the voting instructions provided by your broker, bank, or nominee.

About Silexion Therapuetics
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding the Company’s ability to advance the development of its lead product candidate SIL-204; the Company’s long-term strategic plans and potential strategic initiatives; the Company’s ability to maintain compliance with Nasdaq listing requirements; the potential issuance of additional shares or equity-based incentives; the Company’s ability to attract, retain, and incentivize employees, officers, and directors; and the Company’s future capital requirements and ability to obtain additional financing, are forward-looking statements. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion's ability to successfully complete preclinical studies, proceed with planned regulatory submissions, and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vi) Silexion's ability to maintain its Nasdaq listing; and (vii) other risks and uncertainties set forth in the documents filed by the Company with the SEC, including the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 18, 2025. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.

Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com

Investor Relations
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com

FAQ

What are shareholders voting on at the Silexion (SLXN) EGM on March 16, 2026?

Shareholders will vote to increase authorized share capital and amend the equity plan evergreen. According to the company, proposals seek to raise authorized capital to US$796,500 (59,000,000 shares) and change the 2024 Plan evergreen to yield a 10% fully diluted reserve.

How much will Silexion (SLXN) increase its authorized share capital if approved?

The authorized capital would rise from US$121,500 to US$796,500, expanding shares to 59,000,000. According to the company, this is an increase of 50,000,000 ordinary shares from the current 9,000,000 authorized shares to provide financing and operational flexibility.

What does the 2024 Equity Incentive Plan evergreen change mean for SLXN employees?

The amendment increases the annual evergreen to create a 10% fully diluted equity pool for incentives. According to the company, this change is intended to help attract, retain, and incentivize employees, officers, and directors under the 2024 Plan.

Why does Silexion (SLXN) say voting FOR the proposals matters for SIL-204 development?

Voting FOR enables the company to advance clinical development of SIL-204 and pursue strategic initiatives. According to the company, the capital and equity flexibility are intended to support clinical programs and attract talent needed for execution.

How can SLXN shareholders vote for the March 16, 2026 EGM if they are record or beneficial holders?

Record shareholders may return proxy cards or vote online at www.cstproxyvote.com using their control number; beneficial holders follow broker instructions. According to the company, shareholders needing assistance can contact Laurel Hill Advisory Group at the provided toll-free numbers.